ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
06 juin 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
03 juin 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
31 mai 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update
10 mai 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., May 10, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents,...
ContraFect to Present at the Bacteriophage Therapy Summit
21 mars 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
14 mars 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 14, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference
13 mars 2019 07h00 HE
|
ContraFect Corporation
YONKERS, New York, March 13, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated...
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens
04 mars 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine
13 févr. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Feb. 13, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program
17 janv. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...